Breaking News Instant updates and real-time market news.

DCPH

Deciphera

$44.61

2.73 (6.52%)

04:47
06/19/18
06/19
04:47
06/19/18
04:47

Deciphera downgraded to Neutral from Buy at B. Riley FBR

B. Riley FBR analyst Madhu Kumar downgraded Deciphera Pharmaceuticals to Neutral with an unchanged price target of $43. The analyst cites valuation for the downgrade with the shares up 50% over the past four months.

  • 19

    Jun

DCPH Deciphera
$44.61

2.73 (6.52%)

06/03/18
PIPR
06/03/18
NO CHANGE
Target $35
PIPR
Overweight
Piper Jaffray incrementally positive on Deciphera shares
Piper Jaffray analyst Christopher Raymond is ncrementally positive on Deciphera's (DCPH) shares after what he sees as meaningfully de-risking data for DCC-2618 in refractory GIST at ASCO over the weekend. The analyst sees two key takeaways from the data, namely that DCC-2618 continues to compare well to Blueprint Medicines' (BPMC) BLU-285 efficacy wise, while maintaining a more favorable safety profile, and as he thinks Deciphera's 2L registration trial is meaningfully de-risked, in that sunitinib consistently confers just a single digit ORR. Raymond reiterates an Overweight rating and $35 price target on Deciphera shares.
06/04/18
JPMS
06/04/18
NO CHANGE
Target $33
JPMS
Overweight
Deciphera price target raised to $33 from $30 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for Deciphera to $33 citing the "better-than-expected" phase I update for DCC-2618 at ASCO. The upadted increased the analyst's probability of success in the pivotal 2L Gist trial set to start this year. She keeps an Overweight rating on the shares.
06/12/18
PIPR
06/12/18
NO CHANGE
Target $50
PIPR
Overweight
Deciphera price target raised to $50 from $35 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Deciphera Pharmaceuticals to $50 saying the data at ASCO warrant higher DCC-2618 estimates. The gastrointestinal stromal tumors data are "highly competitive and meaningfully de-risking," Raymond tells investors in a research note. Further, the analyst is taking the opportunity to layer in revenue from "the other large opportunity for this molecule," systemic mastocytosis. He remains a buyer of Deciphera shares with an Overweight rating.
06/15/18
PIPR
06/15/18
NO CHANGE
Target $50
PIPR
Overweight
Piper says Deciphera competitor data highlights opportunity for DCC-2618
Piper Jaffray analyst Christopher Raymond said that Blueprint Medicines (BPMC) presented "impressive efficacy data" at the EHA meeting on BLU-285 in systemic mastocytosis, leading him to think this mechanism in SM continues to make sense. With comparable efficacy data in advanced GIST and, importantly, a better safety profile, he thinks Deciphera's (DCPH) DCC-2618 may "stack up well" against Blueprint's BLU-285, Raymond tells investors. He maintains an Overweight rating and $50 price target on Deciphera shares.

TODAY'S FREE FLY STORIES

ZSAN

Zosano Pharma

$4.19

1.98 (89.59%)

11:40
02/21/19
02/21
11:40
02/21/19
11:40
Recommendations
BTIG boosts Zosano target to $19 on 'solid' migraine safety data »

BTIG analyst Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:38
02/21/19
02/21
11:38
02/21/19
11:38
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

UNIT

Uniti Group

$11.23

-1.035 (-8.44%)

11:35
02/21/19
02/21
11:35
02/21/19
11:35
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 11

    Mar

  • 11

    Mar

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:32
02/21/19
02/21
11:32
02/21/19
11:32
Hot Stocks
Breaking Hot Stocks news story on Zosano Pharma »

Zosano Pharma jumps 100%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Conference/Events
UBS leisure/lodging analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

ZSAN

Zosano Pharma

$3.89

1.68 (76.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zosano says Qtrypta long-term study shows 'well-tolerated safety profile' »

Zosano Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYNE

Zynerba

$4.85

-0.05 (-1.02%)

11:31
02/21/19
02/21
11:31
02/21/19
11:31
Hot Stocks
Zynerba patent listed by World Intellectual Property Organization »

The patent listed by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$24.23

-0.45 (-1.82%)

11:25
02/21/19
02/21
11:25
02/21/19
11:25
Options
JD.com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 04

    Mar

  • 20

    Mar

KMTUY

Komatsu

$0.00

(0.00%)

11:21
02/21/19
02/21
11:21
02/21/19
11:21
Downgrade
Komatsu rating change  »

Komatsu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:20
02/21/19
02/21
11:20
02/21/19
11:20
General news
Treasury announced $113 B in shorter dated coupon sales for next week »

Treasury announced $113 B…

SCI

Service Corp.

$42.31

-0.42 (-0.98%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Hot Stocks
Service Corp. raises quarterly cash dividend 6% to 18c per share »

Service Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/21/19
02/21
11:17
02/21/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/21/19
02/21
11:16
02/21/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
02/21/19
02/21
11:15
02/21/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

GS

Goldman Sachs

$197.12

-1.49 (-0.75%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Initiation
Goldman Sachs initiated  »

Odeon's Dick Bove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

  • 12

    Mar

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

DK

Delek US

$36.95

-0.13 (-0.35%)

11:10
02/21/19
02/21
11:10
02/21/19
11:10
Options
Delek US draws upside call buyers as shares slip off early highs »

Delek US draws upside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
02/21/19
02/21
11:10
02/21/19
11:10
General news
Existing home sales fell 1.2% in January to 4.99 M, a 3-year low »

Existing home sales fell…

11:08
02/21/19
02/21
11:08
02/21/19
11:08
General news
3-Month Bill Announcement CUSIP Number data reported »

3-Month Bill Announcement…

MNST

Monster Beverage

$58.64

-0.07 (-0.12%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Options
Monster Beverage option volume spikes to 3X daily average amid active trading »

Monster Beverage option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LIVN

LivaNova

$98.56

-1.32 (-1.32%)

11:07
02/21/19
02/21
11:07
02/21/19
11:07
Recommendations
LivaNova analyst commentary  »

Piper says Japanese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

UBCP

United Bancorp

$10.95

(0.00%)

11:04
02/21/19
02/21
11:04
02/21/19
11:04
Hot Stocks
United Bancorp raises quarterly cash dividend to 13.25c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIVN

LivaNova

$98.59

-1.29 (-1.29%)

11:03
02/21/19
02/21
11:03
02/21/19
11:03
Hot Stocks
LivaNova announces national reimbursement in Japan for Perceval valve for AVD »

LivaNova announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

  • 07

    May

  • 08

    May

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.